Paik J H, Jeon Y K, Park S S, Kim Y A, Kim J E, Huh J, Lee S-S, Kim W H, Kim C W
Department of Pathology and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Histopathology. 2005 Sep;47(3):281-91. doi: 10.1111/j.1365-2559.2005.02222.x.
To evaluate the different expression patterns and the prognostic significance of cell cycle regulatory molecules in diffuse large B-cell lymphomas (DLBCLs) of germinal centre (GC) and non-GC phenotypes.
Tissue microarray slides composed of 126 extranodal and 88 nodal DLBCLs were immunostained for p16, p21, p27, p14 and p53. DLBCLs were classified into GC and non-GC phenotype according to the immunohistochemical expression of bcl-6, CD10, and MUM1. Aberrant expression of p53 was more frequent in the GC phenotype in nodal cases (P = 0.038), and the loss of p16, p21 and p14 expression was significantly more common in the non-GC phenotype (P = 0.004, P = 0.001, P < 0.001). Concurrent disruptions of the p16-Rb and p14-p53 pathways as represented by the immunoprofile of p16/p14/p53 (-/-/+) were associated with a poor prognosis in the GC phenotype [mean survival 31 months in the p16/p14/p53 (-/-/+) group versus 62 months in the other groups, P =0.0485].
The expression and prognostic implications of cell cycle regulatory molecules differ between GC and non-GC phenotypes in DLBCLs. The immunoprofile of p16/p14/p53 (-/-/+) within the GC phenotype of DLBCLs can be defined as a poor prognostic subgroup.
评估细胞周期调节分子在生发中心（GC）型和非GC型弥漫性大B细胞淋巴瘤（DLBCL）中的不同表达模式及其预后意义。
对由126例结外和88例结内DLBCL组成的组织微阵列玻片进行p16、p21、p27、p14和p53免疫染色。根据bcl-6、CD10和MUM1的免疫组化表达将DLBCL分为GC型和非GC型。在结内病例中，p53的异常表达在GC型中更常见（P = 0.038），而p16、p21和p14表达缺失在非GC型中明显更常见（P = 0.004、P = 0.001、P < 0.001）。以p16/p14/p53（-/-/+）免疫表型为代表的p16-Rb和p14-p53通路同时中断与GC型预后不良相关[p16/p14/p53（-/-/+）组平均生存31个月，其他组为62个月，P = 0.0485]。
DLBCL中GC型和非GC型细胞周期调节分子的表达及预后意义不同。DLBCL的GC型中p16/p14/p53（-/-/+）免疫表型可被定义为预后不良亚组。
